Program Purpose
Specifically designed by the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE- and CNE-certified programs. Presented by leading and local authorities in tumor immunology and cancer immunotherapy, these six-hour programs will facilitate understanding of:
- The rationale for common approaches to immunotherapy
- The clinical applications of immunotherapy for disease states with FDA-approved treatments (melanoma, and lung, genitourinary, hematologic, and head and neck cancers)
- Operational and reimbursement barriers to implementing immunotherapy in a community setting and strategies to overcome them
- The identification and management of immune-related adverse events from the nursing and prescriber perspective in the clinic and emergency settings
Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the live event, through two post-program webinars, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice. Breakfast and lunch will be served at the live portion of this event.
For more information, including program objectives, click here.
This program is presented in collaboration with the American Academy of Emergency Medicine (AAEM) and the Association of Community Cancer Centers (ACCC).
The 2017 - 2016 Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants from Aduro Biotech, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Incyte Corporation, Merck & Co., Inc. and Prometheus Laboratories Inc.